home / stock / bmbif / bmbif quote
Last: | $7.98 |
---|---|
Change Percent: | -1.85% |
Open: | $8.52 |
Close: | $7.98 |
High: | $8.52 |
Low: | $7.75 |
Volume: | 61,753 |
Last Trade Date Time: | 11/05/2021 04:54:29 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$7.98 | $8.52 | $7.98 | $8.52 | $7.75 | 61,753 | 11-05-2021 |
$8.13 | $8.295 | $8.13 | $8.34 | $8.12 | 26,261 | 11-04-2021 |
$8.23 | $7.44282 | $8.23 | $8.92 | $7.4428 | 74,719 | 11-03-2021 |
$7.25 | $7.3893 | $7.25 | $7.3893 | $7.25 | 3,409 | 11-02-2021 |
$7.3244 | $7.22 | $7.3244 | $7.41 | $7.22 | 3,998 | 11-01-2021 |
$7.12 | $6.937 | $7.12 | $7.12 | $6.89 | 8,950 | 10-29-2021 |
$6.98 | $7.057 | $6.98 | $7.07 | $6.9151 | 5,516 | 10-28-2021 |
$6.98 | $6.98499 | $6.98 | $6.985 | $6.9247 | 2,102 | 10-27-2021 |
$7.038 | $6.8159 | $7.038 | $7.038 | $6.7916 | 2,774 | 10-26-2021 |
$6.82 | $6.72 | $6.82 | $6.87 | $6.7 | 7,302 | 10-25-2021 |
$6.7096 | $6.77616 | $6.7096 | $6.7762 | $6.341 | 53,722 | 10-22-2021 |
$6.782 | $7.1 | $6.782 | $7.1 | $6.4724 | 30,863 | 10-21-2021 |
$7.154 | $7.2895 | $7.154 | $7.29 | $7.1391 | 3,733 | 10-20-2021 |
$7.1885 | $7.32 | $7.1885 | $7.355 | $7.1 | 8,448 | 10-19-2021 |
$7.33 | $7.43 | $7.33 | $7.43 | $7.33 | 3,000 | 10-18-2021 |
$7.43 | $7.487 | $7.43 | $7.487 | $7.3455 | 2,460 | 10-15-2021 |
$7.49 | $7.49 | $7.49 | $7.5 | $7.4235 | 9,651 | 10-14-2021 |
$7.4039 | $7.43682 | $7.4039 | $7.4368 | $7.3555 | 1,192 | 10-13-2021 |
$7.42 | $7.59028 | $7.42 | $7.85 | $7.4199 | 18,044 | 10-12-2021 |
$7.84 | $7.4 | $7.84 | $8 | $7.257 | 13,950 | 10-11-2021 |
News, Short Squeeze, Breakout and More Instantly...
Bright Minds Biosciences Inc Com Company Name:
BMBIF Stock Symbol:
OTCMKTS Market:
Bright Minds Biosciences Inc Com Website:
-- BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascend...
-- BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- BMB-101 demonstrated an excellent safety and tolerability profile in single ascendin...
VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatr...